Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents

22 Aug 2012

Abstract excerpt

Platinum-based antitumor agents are widely used in cancer chemotherapy. Drug resistance is a major obstacle to the successful use of these agents because once drug resistance develops, other effective treatment options are limited. Recently, we conducted a clinical trial using a copper-lowering agent to overcome platinum drug resistance in ovarian cancer patients and the preliminary results are encouraging. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Metal complexes synthesis and properties
Share to Trace Elements in Health

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22914438
DOI: 10.1158/1535-7163.mct-12-0580

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating AgentsPMID 22914438Read ↗

Role of copper transporters in platinum resistanceSemantic proximity Read ↗

Role of the Human High-Affinity Copper Transporter in Copper Homeostasis Regulation and Cisplatin Sensitivity in Cancer ChemotherapySemantic proximity Read ↗

Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer.Semantic proximity Read ↗

Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.Semantic proximity Read ↗

The contribution of copper efflux transporters ATP7A and ATP7B to chemoresistance and personalized medicine in ovarian cancerSemantic proximity Read ↗

Ovarian Cancer—Insights into Platinum Resistance and Overcoming ItSemantic proximity Read ↗

Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7BThis paper is one of a selection of papers published in a Special Issue entitled CSBMCB 53rd Annual Meeting — Membrane Proteins in Health and Disease, and has undergone the Journal’s usual peer review process.Semantic proximity Read ↗

A Re-Evaluation of the Role of hCTR1, the Human High-Affinity Copper Transporter, in Platinum-Drug Entry into Human CellsSemantic proximity Read ↗

Molecular mechanisms of cisplatin resistance in ovarian cancerSemantic proximity Read ↗

Copper: An Intracellular Achilles’ Heel Allowing the Targeting of Epigenetics, Kinase Pathways, and Cell Metabolism in Cancer TherapeuticsSemantic proximity Read ↗

Mechanistic Comparison of Human High-Affinity Copper Transporter 1-Mediated Transport between Copper Ion and CisplatinSemantic proximity Read ↗

Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.